(Q39395884)

11 September 2017

title

Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity (English)

1 reference

11 September 2017

1 reference

Wenzhong Que

1

1 reference

11 September 2017

Junmin Chen

series ordinal

2

1 reference

11 September 2017

Ma Chuang

series ordinal

3

1 reference

11 September 2017

Danrong Jiang

series ordinal

4

1 reference

11 September 2017

publication date

11 November 2011

1 reference

Acta Pathologica et Microbiologica Scandinavica

11 September 2017

published in

1 reference

11 September 2017

volume

120

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

195-203

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

11 September 2017

1 reference

A review of the proteasome inhibitor bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Novel biological therapies for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Stem cell transplantation in multiple myeloma (0, 1, or 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Bortezomib for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of beta-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Tyrosine kinase receptor indistinguishable from the c-met protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

PI3K/Akt/mTOR pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Hepatocyte growth factor promotes migration of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

C-MET as a new therapeutic target for the development of novel anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2011.02836.X

10.1111/J.1600-0463.2011.02836.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference